| Date | Title | Description |
| 08.11.2025 | AAVantgarde Secures $141M for Groundbreaking Gene Therapies | AAVantgarde Bio closed a $141 million Series B round. This substantial funding propels gene therapy programs for inherited retinal diseases. Key targets: Stargardt disease and Usher Syndrome Type 1B. Both represent severe conditions with no... |
| 06.11.2025 | AAVantgarde Closes $141M Series B Financing | AAVantgarde Bio, a Milan, Italy-based clinical-stage, biotechnology company developing therapies for inherited retinal diseases (IRDs), raised $141M in Series B funding.
The round was led by Schroders Capital, as well as existing investors ... |
| 03.11.2025 | Italian biotech AAVantgarde adds $141M series B to fund retinal disease gene therapy trials | Amgen Ventures-backed AAVantgarde Bio has raised $141 million in series B funding that the Italian biotech will use to push its two eye disease gene therapies through the clinic.
One of these assets, dubbed AAVB-039, is currently undergoing... |
| 12.08.2025 | AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease | MILAN, August 12, 2025 — AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has gr... |
| 15.07.2025 | AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial | - AAVB-039 delivers the full-length ABCA4 -protein, addressing the root cause of the disease and enabling treatment of all patients, independent of mutation
- CELESTE is informed by the STELLA prospective natural history study, which is cur... |
| 03.05.2024 | AAVantgarde presents the design of its innovative LUCE-1 trial for USH1B at the 9th Annual Retinal Cell and Gene Therapy Innovation Summit | May 3, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the presentation of... |
| 23.04.2024 | AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting | MILAN, Italy, April 23, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, ... |
| 23.04.2024 | AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting | April 23, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces the publication ... |
| - | AAVantgarde Bio | - |
